Companies › Black Diamond Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| silevertinib (BDTX-1535) 4th generation irreversible EGFR inhibitor targeting classical and non-classical driver an | EGFR | Phase 2 | Glioblastoma (GBM); Non-Small Cell Lung Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05256290 | silevertinib (BDTX-1535) | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07326566 | silevertinib (BDTX-1535) | Phase 2 | Glioblastoma (GBM) | Oncology | Nov 2028 |
Cash and short-term investments of $102m on 2026-09-30; operating cash outflow about $36m a year; runway about 34 months at that burn, to Aug 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Wayshine Biopharm ArriVent BioPharma Teligene US Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.